Which dose of tirzepatide works best for weight loss?

What the SURMOUNT-1 results actually tell us about dose and weight loss

The SURMOUNT-1 trial enrolled 2,539 adults with obesity and no type 2 diabetes, randomising participants to 5 mg, 10 mg or 15 mg tirzepatide (or placebo) over 72 weeks. The results, published in the New England Journal of Medicine, showed a clear relationship between dose and weight reduction: the 5 mg group lost around 15% on average, the 10 mg group around 19.5%, and the 15 mg group around 20–21%. That dose-response pattern is the strongest signal we have that higher doses produce greater average loss, but the word "average" matters.

Population averages hide enormous individual variation. Some people in the 10 mg arm lost more than the average 15 mg participant. Genetics, starting weight, metabolic history, how well someone tolerates gastrointestinal effects, and whether lifestyle changes are sustained alongside treatment all influence where an individual lands. The trial data set a reasonable expectation; they don't predict a personal outcome.

NICE's appraisal of tirzepatide (TA1026) drew on this evidence when recommending the medicine for NHS use, and its guidance reinforces that treatment should be reviewed if less than 5% weight loss has occurred after six months at the highest tolerated dose. That review threshold is built around the dose question too: "highest tolerated" is doing real work in that sentence. You can read the NICE tirzepatide guidance in full.

Why the dose escalation schedule exists, and why rushing it backfires

Treatment begins at 2.5 mg. The job of that first pen is settling your digestive system into the medicine, not producing measurable fat loss. Nausea, reflux and a changed appetite signal that tirzepatide is working on the gut hormone pathways it is designed to act on; the slow start reduces how sharply those effects hit. Most people find GI symptoms are most noticeable in the first one to two weeks after a dose change, then ease off.

From 2.5 mg, the licensed schedule moves up in 2.5 mg steps, typically every four weeks, guided by the prescriber's clinical assessment. Skipping steps or increasing sooner than recommended tends to amplify side effects without meaningfully accelerating weight loss, the body needs time to adapt at each level. The full tirzepatide dose schedule covers what each step involves in more detail.

People sometimes ask about staying on 2.5 mg longer than intended, usually because of side effects or a supply gap. A prescriber can advise on that; it is not a decision to make unilaterally. Similarly, if you are curious about what 15 mg involves and who reaches it, that page covers the evidence in full.

Tolerance, not ambition, sets the ceiling

The goal is not always 15 mg. For many people, 10 mg delivers clinically meaningful weight reduction with manageable side effects, and a prescriber who sees that a patient is stable, losing weight steadily, and tolerating treatment well may decide there is no clinical reason to push higher. That is good medicine, not a failure to reach the top of the ladder.

For others, 15 mg is reached without difficulty and produces substantial results. Starting at 5 mg is sometimes discussed for patients who have already completed the 2.5 mg period elsewhere; the 5 mg pen on its own has a specific clinical context that a prescriber reviews. The point is that dose decisions are individual and ongoing, not a fixed plan set on day one and forgotten.

Gastrointestinal effects (nausea, loose stools, slower gastric emptying) are the most common reason people pause titration or settle at a lower maintenance dose. Eating smaller meals, prioritising protein and staying well hydrated tend to help. Practical questions like these are exactly the kind of thing to raise with an aftercare team; common questions about treatment are answered on the FAQs page, and our support team is available seven days a week. If you want to understand what private treatment through a regulated online pharmacy involves, the Mounjaro treatment overview is a good starting point, and for cost context, the Mounjaro pricing page sets out what is included in one transparent figure. The NHS tirzepatide information page is also worth reading for a plain-English summary of the medicine.

Dose changes (whether increases or stepping back temporarily) always go through a prescriber. That is true at nume, where every repeat order receives a fresh clinical review before dispatch. It's a question our prescribers field most weeks: "can I just stay at this dose?" The answer is always worked out with the person in front of them, not from a protocol sheet.

If you want a prescriber to look at where you are in your journey and advise on the right dose for you, checking your eligibility is where that conversation starts.